Chidamide in Combination With Vincristine Metronomic Chemotherapy for Advanced Triple-negative Breast Cancer
A Prospective, Single-arm, Open-lable, Single-center Phase Ib/II Clinical Study of Chidamide in Combination With Vincristine Metronomic Chemotherapy for Advanced Triple-negative Breast Cancer
Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
This PHASE1/PHASE2 trial investigates Breast Cancer and Chemotherapy Effect and is currently ongoing. Cancer Institute and Hospital, Chinese Academy of Medical Sciences leads this study, which shows 4 recorded versions since 2022 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
4 versions recorded-
Mar 2025 — Present [monthly]
Unknown PHASE1/PHASE2
Status: Recruiting → Unknown
-
Sep 2024 — Mar 2025 [monthly]
Recruiting PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Mar 2023 — Jul 2024 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Nov 2022
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
For direct contact, visit the study record on ClinicalTrials.gov .